MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 36.94 Million EUR | 25.93% |
| 2022 | 29.33 Million EUR | -33.78% |
| 2021 | 44.3 Million EUR | -30.35% |
| 2020 | 63.6 Million EUR | 132.93% |
| 2019 | 27.3 Million EUR | -28.11% |
| 2018 | 37.98 Million EUR | 49.81% |
| 2017 | 25.35 Million EUR | 8.97% |
| 2016 | 23.26 Million EUR | 108.24% |
| 2015 | 11.17 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 50.48 Million EUR | 0.0% |
| 2023 Q4 | 36.94 Million EUR | 0.0% |
| 2023 FY | 36.94 Million EUR | 25.93% |
| 2022 FY | 29.33 Million EUR | -33.78% |
| 2022 Q4 | 29.33 Million EUR | 0.0% |
| 2022 Q2 | 32.77 Million EUR | 0.0% |
| 2021 FY | 44.3 Million EUR | -30.35% |
| 2021 Q2 | 54.79 Million EUR | 0.0% |
| 2021 Q4 | 44.3 Million EUR | 0.0% |
| 2020 Q2 | 41.31 Million EUR | 0.0% |
| 2020 Q4 | 63.6 Million EUR | 0.0% |
| 2020 FY | 63.6 Million EUR | 132.93% |
| 2019 FY | 27.3 Million EUR | -28.11% |
| 2019 Q2 | 35.26 Million EUR | 0.0% |
| 2019 Q4 | 27.3 Million EUR | 0.0% |
| 2018 Q4 | 37.98 Million EUR | 0.0% |
| 2018 FY | 37.98 Million EUR | 49.81% |
| 2018 Q3 | 37.98 Million EUR | 44.42% |
| 2018 Q2 | 26.29 Million EUR | 0.0% |
| 2018 Q1 | 26.29 Million EUR | 3.73% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q3 | 25.35 Million EUR | 0.0% |
| 2017 Q4 | 25.35 Million EUR | 0.0% |
| 2017 FY | 25.35 Million EUR | 8.97% |
| 2016 FY | 23.26 Million EUR | 108.24% |
| 2015 FY | 11.17 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -151.176% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 88.703% |
| Adocia SA | 24.95 Million EUR | -48.053% |
| Aelis Farma SA | 26.28 Million EUR | -40.588% |
| Biophytis S.A. | 11.93 Million EUR | -209.551% |
| Advicenne S.A. | 12.4 Million EUR | -197.8% |
| genOway Société anonyme | 31.84 Million EUR | -16.034% |
| IntegraGen SA | 8 Million EUR | -361.83% |
| Medesis Pharma S.A. | 1.92 Million EUR | -1818.046% |
| Neovacs S.A. | 47.53 Million EUR | 22.27% |
| NFL Biosciences SA | 3.97 Million EUR | -830.533% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -147.758% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -886.129% |
| Sensorion SA | 46.49 Million EUR | 20.532% |
| Theranexus Société Anonyme | 7.23 Million EUR | -410.491% |
| TME Pharma N.V. | 2.49 Million EUR | -1383.26% |
| Valbiotis SA | 33.24 Million EUR | -11.128% |
| TheraVet SA | 7.53 Million EUR | -390.404% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -4.746% |
| argenx SE | 4.11 Billion EUR | 99.101% |
| BioSenic S.A. | 9.55 Million EUR | -286.526% |
| Celyad Oncology SA | 16.28 Million EUR | -126.925% |
| DBV Technologies S.A. | 165.65 Million USD | 77.695% |
| Galapagos NV | 4.35 Billion EUR | 99.152% |
| Genfit S.A. | 173.87 Million EUR | 78.75% |
| GeNeuro SA | 6.31 Million EUR | -485.278% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 22.51% |
| Innate Pharma S.A. | 184.19 Million EUR | 79.941% |
| Inventiva S.A. | 69.13 Million EUR | 46.56% |
| MaaT Pharma SA | 42.93 Million EUR | 13.936% |
| Nanobiotix S.A. | 93.89 Million EUR | 60.651% |
| Onward Medical N.V. | 43.62 Million EUR | 15.313% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 65.437% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 54.886% |
| Oxurion NV | 6.55 Million EUR | -464.092% |
| Pharming Group N.V. | 426.33 Million EUR | 91.334% |
| Poxel S.A. | 4.82 Million EUR | -666.079% |
| GenSight Biologics S.A. | 9.08 Million EUR | -306.603% |
| Transgene SA | 45.21 Million EUR | 18.287% |
| Financière de Tubize SA | 1.92 Billion EUR | 98.076% |
| UCB SA | 15.53 Billion EUR | 99.762% |
| Valneva SE | 469.39 Million EUR | 92.129% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -19.848% |